Goedemiddag allen.
even voorstellen, Ik ben dakdekker van beroep en als nickname.
Ben niet helemaal nieuw op IEX, maar weet de oude gegevens niet meer dus opnieuw aangemeld. Oude account was in 2009 dus is al ff geleden.
Zat toen redelijk veel in bio/pharma aandeeltjes en nu dus weer.
Ik heb mijn hoop gevestigd op Bionor. Ik kreeg daar een goed gevoel bij.
Nu 2 dagen in bezit en een stijging van 20% op deze kleine aandeeltjes.
Nu hopen dat ze iets leuks in petto hebben en skyhigh gaan.
Beetje info van de website:
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a possible functional HIV cure.
Bionor Pharma ASA is the result of a 2010 acquisition of the vaccine developer Bionor Immuno AS by the nutraceutical company Nutri Pharma ASA (which was listed on Oslo Børs since 2000 and later changed its name to Bionor Pharma ASA).
Bionor Immuno AS was a spin-off from Bionor AS, founded in 1985 in Skien, Norway with a focus on developing diagnostic tests for viral diseases. The combined group of Bionor Immuno AS and Nutri Pharma ASA decided to leverage its immunology expertise by exploring the use of its proprietary compounds for viral diseases in the development of peptide vaccines.
In 2011, the Group sold Nutri Pharma ASA’s Nutrilett® brand to a subsidiary of Orkla ASA, a Norwegian company, using the proceeds of the sale to finance the company’s vaccine research.
Since then, the company has ceased its nutraceutical operations and its main focus has been on the development of vaccines for viral infections, primarily HIV.
History and development
An early sample of the vaccine.
Year Milestone
1985 Bionor AS founded in Skien, Norway
1999 First use of Vacc-4x in humans
2000 Initial public offering and listing of Nutri Pharma ASA on Oslo Børs
2004 Grant of Vacc-4x patent in the U.S.
2010 Acquisition of Bionor Immuno AS by Nutri Pharma ASA in February 2010; name change to Bionor Pharma ASA
2011 Nutrilett® brand sold to a subsidiary of Orkla ASA
2013 Launch of 'Shock & Kill' therapeutic strategy
2014 Vacc-4x monotherapy trial results reported and
2014 REDUC Part A results presented at IAS 2014
2015 Interim analysis of REDUC Part B trial results reported
2015 Romidepsin supply agreement with Celgene for planned BIOSKILL clinical trial
2015 New strategy and long-term development plans announced
2015 Successful completion of the REDUC trial